Summary
Global Markets Direct’s, ‘Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016’, provides an overview of the Valeant Pharmaceuticals International, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Valeant Pharmaceuticals International, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Valeant Pharmaceuticals International, Inc.
- The report provides overview of Valeant Pharmaceuticals International, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Valeant Pharmaceuticals International, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Valeant Pharmaceuticals International, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Valeant Pharmaceuticals International, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Valeant Pharmaceuticals International, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Valeant Pharmaceuticals International, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Valeant Pharmaceuticals International, Inc. Snapshot 7
Valeant Pharmaceuticals International, Inc. Overview 7
Key Information 7
Key Facts 7
Valeant Pharmaceuticals International, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Valeant Pharmaceuticals International, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Valeant Pharmaceuticals International, Inc. - Pipeline Products Glance 18
Valeant Pharmaceuticals International, Inc. - Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Valeant Pharmaceuticals International, Inc. - Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Valeant Pharmaceuticals International, Inc. - Early Stage Pipeline Products 22
Preclinical Products/Combination Treatment Modalities 22
Valeant Pharmaceuticals International, Inc. - Unknown Stage Pipeline Products 23
Unknown Products/Combination Treatment Modalities 23
Valeant Pharmaceuticals International, Inc. - Drug Profiles 24
brodalumab 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(halobetasol propionate + tazarotene) 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
budesonide 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
IDP-122 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
loteprednol etabonate next generation 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
rifaximin DR 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BLO-020 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ezogabine 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
IDP-120 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
IDP-121 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
IDP-125 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
IDP-126 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
IDP-127 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
IDP-128 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
IDP-129 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
IDP-130 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
IDP-131 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
lapuleucel-T 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ribavirin 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SAL-021 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Product Description 51
Mechanism of Action 51
R&D Progress 51
SPT-201 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
metyrosine 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BLO-021 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
IDP-123 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
IDP-124 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
VALBRO-03 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Valeant Pharmaceuticals International, Inc. - Pipeline Analysis 58
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Target 58
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Route of Administration 60
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Molecule Type 61
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action 62
Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates 64
Valeant Pharmaceuticals International, Inc. - Dormant Projects 73
Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products 75
Discontinued Pipeline Product Profiles 75
ATON-004 75
(bupropion hydrochloride + selective serotonin reuptake inhibitor) 75
brodalumab 75
CVTE-002 76
ezogabine 76
IDP-107 76
IDP-109 76
IDP-115 76
MC-5 76
methylnaltrexone bromide 76
pegaptanib sodium 76
rifaximin 76
RUS-350 77
taribavirin hydrochloride 77
tiazofurin 77
UK-279276 77
Valeant Pharmaceuticals International, Inc. - Company Statement 78
Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries 81
Head Office 81
Other Locations & Subsidiaries 81
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90
List of Tables
Valeant Pharmaceuticals International, Inc., Key Information 7
Valeant Pharmaceuticals International, Inc., Key Facts 7
Valeant Pharmaceuticals International, Inc. - Pipeline by Indication, 2016 9
Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2016 11
Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2016 12
Valeant Pharmaceuticals International, Inc. - Combination Treatment Modalities in Pipeline, 2016 13
Valeant Pharmaceuticals International, Inc. - Partnered Products in Pipeline, 2016 14
Valeant Pharmaceuticals International, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 15
Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2016 16
Valeant Pharmaceuticals International, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 17
Valeant Pharmaceuticals International, Inc. - Pre-Registration, 2016 18
Valeant Pharmaceuticals International, Inc. - Phase III, 2016 19
Valeant Pharmaceuticals International, Inc. - Phase II, 2016 20
Valeant Pharmaceuticals International, Inc. - Phase I, 2016 21
Valeant Pharmaceuticals International, Inc. - Preclinical, 2016 22
Valeant Pharmaceuticals International, Inc. - Unknown, 2016 23
Valeant Pharmaceuticals International, Inc. - Pipeline by Target, 2016 59
Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2016 60
Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2016 61
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action, 2016 63
Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates, 2016 64
Valeant Pharmaceuticals International, Inc. - Dormant Developmental Projects,2016 73
Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products, 2016 75
Valeant Pharmaceuticals International, Inc., Other Locations 81
Valeant Pharmaceuticals International, Inc., Subsidiaries 81
List of Figures
Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Indication, 2016 9
Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2016 11
Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2016 12
Valeant Pharmaceuticals International, Inc. - Partnered Products in Pipeline, 2016 14
Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2016 16
Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Target, 2016 58
Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2016 60
Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2016 61
Valeant Pharmaceuticals International, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 62
